TY - JOUR T1 - Characterization of a Human Keratinocyte HaCaT Cell Line Model to Study the Regulation of CYP2S1 A1 - McNeilly,Alison D. A1 - Woods,Julie A. A1 - Ibbotson,Sally H. A1 - Wolf,C. Roland A1 - Smith,Gillian AU - McNeilly,Alison D. AU - Woods,Julie A. AU - Ibbotson,Sally H. AU - Wolf,C. Roland AU - Smith,Gillian PY - 2012/2 Y1 - 2012/2 N2 -

CYP2S1 is an extrahepatic cytochrome P450 (P450) that shows marked individuality in constitutive and inducible expression. CYP2S1 mRNA expression is increased in psoriasis and by treatments for psoriasis, including retinoids and UV radiation, although endogenous substrates remain poorly characterized. Because previous model systems have overexpressed modified CYP2S1 in bacteria, human HaCaT keratinocyte cells were screened for constitutive and regulatable CYP2S1 expression and CYP2S1 activity in HaCaT cells compared with a novel Chinese hamster ovary (CHO)-based cell line engineered to stably coexpress CYP2S1 and NADPH cytochrome P450 reductase. Constitutive mRNA expression for CYP2S1 and additional P450s, retinoid acid receptors (RAR alpha, RAR beta, RAR gamma), and retinoid X receptors (RXR alpha, RXR beta and RXR gamma) was assessed by quantitative reverse transcription-polymerase chain reaction (qRT-PCR) analysis in HaCaT cells. Cells were then exposed to retinoids or to UV radiation (UVR), and changes in CYP2S1 mRNA abundance were further examined by qRT-PCR analysis. P450 expression in HaCaT cells was similar to human skin, with abundant CYP2S1 expression. RAR alpha and RAR gamma (but not RAR beta) and all RXR isoforms were also detectable. All-trans retinoic acid (atRA) induced CYPS1 mRNA expression more potently than 9-cis RA or 13-cis RA. P450-dependent atRA metabolism was demonstrated in HaCaT cells, with a very similar metabolite profile to that produced by our CYP2S1-expressing CHO cells. CYP2S1 mRNA expression was also induced by UVR, more potently than CYP1B1, a known UVR-inducible P450. Our results demonstrate regulatable and functional CYP2S1 expression in HaCaT cells, thus identifying a human cell line model with utility for further analysis of CYP2S1 regulation and substrate specificity.

AB -

CYP2S1 is an extrahepatic cytochrome P450 (P450) that shows marked individuality in constitutive and inducible expression. CYP2S1 mRNA expression is increased in psoriasis and by treatments for psoriasis, including retinoids and UV radiation, although endogenous substrates remain poorly characterized. Because previous model systems have overexpressed modified CYP2S1 in bacteria, human HaCaT keratinocyte cells were screened for constitutive and regulatable CYP2S1 expression and CYP2S1 activity in HaCaT cells compared with a novel Chinese hamster ovary (CHO)-based cell line engineered to stably coexpress CYP2S1 and NADPH cytochrome P450 reductase. Constitutive mRNA expression for CYP2S1 and additional P450s, retinoid acid receptors (RAR alpha, RAR beta, RAR gamma), and retinoid X receptors (RXR alpha, RXR beta and RXR gamma) was assessed by quantitative reverse transcription-polymerase chain reaction (qRT-PCR) analysis in HaCaT cells. Cells were then exposed to retinoids or to UV radiation (UVR), and changes in CYP2S1 mRNA abundance were further examined by qRT-PCR analysis. P450 expression in HaCaT cells was similar to human skin, with abundant CYP2S1 expression. RAR alpha and RAR gamma (but not RAR beta) and all RXR isoforms were also detectable. All-trans retinoic acid (atRA) induced CYPS1 mRNA expression more potently than 9-cis RA or 13-cis RA. P450-dependent atRA metabolism was demonstrated in HaCaT cells, with a very similar metabolite profile to that produced by our CYP2S1-expressing CHO cells. CYP2S1 mRNA expression was also induced by UVR, more potently than CYP1B1, a known UVR-inducible P450. Our results demonstrate regulatable and functional CYP2S1 expression in HaCaT cells, thus identifying a human cell line model with utility for further analysis of CYP2S1 regulation and substrate specificity.

KW - HUMAN CYTOCHROME P4502S1 KW - XENOBIOTIC-METABOLIZING ENZYMES KW - RETINOIC ACID METABOLISM KW - B EXPOSURE KW - EXPRESSION KW - IDENTIFICATION KW - PSORIASIS KW - RECEPTOR KW - TRANSCRIPTION KW - P450CYP2S1 U2 - 10.1124/dmd.111.042085 DO - 10.1124/dmd.111.042085 M1 - Article JO - Drug Metabolism and Disposition JF - Drug Metabolism and Disposition SN - 0090-9556 IS - 2 VL - 40 SP - 283 EP - 289 ER -